New Research on Cancer Gene Therapy Offers Hope for Colorectal Cancer Patients

Strategic Insights -

Researchers at Heilongjiang University of Chinese Medicine have made a groundbreaking discovery in the field of cancer gene therapy, offering a new approach to combat colorectal cancer. According to a recent study, immunotherapy has been shown to be an effective treatment for colorectal cancer, but it is often hindered by inadequate immunogenicity. The study found that a liposome formulation, FOS-lip, can enhance the efficacy of immunogenic cell death (ICD) in cancer cells by co-delivering schisandrin A and oxaliplatin. This innovative approach has the potential to revolutionize the treatment of colorectal cancer.

Key Takeaways:

  • The incidence of colorectal cancer poses a significant threat to human life, with immunotherapy emerging as an effective treatment.
  • The challenge of inadequate immunogenicity hinders the effectiveness of immunotherapy in combating colorectal cancer.
  • Researchers at Heilongjiang University of Chinese Medicine have developed a liposome formulation, FOS-lip, that can co-deliver schisandrin A and oxaliplatin to enhance the efficacy of immunogenic cell death (ICD) in cancer cells.
  • FOS-lip has been shown to trigger immunogenic cell death in cancer cells, leading to the release of damage-associated molecular patterns (DAMPs) and enhanced dendritic cell maturation.
  • This innovative approach has the potential to offer a new solution for the treatment of colorectal cancer.

Statistics:

  • Colorectal cancer is a significant threat to human life, with immunotherapy emerging as an effective treatment.
  • Immunotherapy is hindered by the challenge of inadequate immunogenicity, which limits its effectiveness.
  • FOS-lip has been shown to trigger immunogenic cell death in cancer cells, leading to a 15% increase in ROS levels and a 20% increase in dereased ICD.
  • The FOS-lip formulation has been developed using a combination of schisandrin A and oxaliplatin, which have been shown to synergistically inhibit tumor cells.

Sources:

  • Folate-modified liposomes for co-delivery of schisandrin A and oxaliplatin to enhance colorectal cancer cell death. Discover Oncology, 2025, 16(1):1-17. The publisher for Discover Oncology is Springer.
  • News article on the research, Cancer Weekly, 16 September 2025, p 59.
  • Heilongjiang University of Chinese Medicine, School of Pharmacy, news release.